A phase 2 trial of PUL-042 in advanced solid tumours, run by Pulmotect, Inc., now recruiting.
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) is a phase 2 interventional study registered as NCT06665100 by Pulmotect, Inc., with 100 participants planned, started 2025-06-27 and due to reach its primary completion in 2027-04. Interventions recorded: PUL-042 and Placebo.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.